【摘要】 目的:评价多西紫杉醇联合顺铂、5-氟尿嘧啶方案(DCF方案)治疗晚期胃癌的临床疗效和不良反应。方法:DCF方案治疗晚期胃癌患者37例。多西紫杉醇45mg/m2,静滴1h,d1、8;5-氟尿嘧啶(5-FU)375mg/m2,持续静脉泵(Graseby泵)点滴24h,d1-5;顺铂20mg/m2,d1-5;28天为1个周期。用药至少2个周期后评价疗效和不良反应。结果:全组34例可评价疗效,完全缓解(CR)1例,部分缓解(PR)14例,稳定(SD)15例,进展(PD)4例,有效率(RR)为44.1%。中位进展时间(TTP)为6.1个月,中位生存期为9.3个月,1年生存率28.2%。其中初治组有效率为52.6%(10/19),有1例CR;复治组有效率为33.3%(5/15),无CR病例,两组无显著差异(P>0.05)。不良反应主要为骨髓抑制、消化系反应和脱发。大部分患者为Ⅰ、Ⅱ度反应,耐受良好。其中白细胞减少27例(79.4%),Ⅲ-Ⅳ度8例(23.5%)。结论:多西紫杉醇联合顺铂、5-氟尿嘧啶组成DCF方案治疗进展期胃癌疗效较好,不良反应可以耐受,值得临床进一步探讨。更多还原

【Abstract】 Objective:To evaluate the efficiency and toxicity of docetaxel combined with 5-fluorouracil and cisplatin (DCF) regimen in patients with advanced gastric cancer.Methods:Thirty-seven patients with advanced gastric cancer diagnosed pathologically were enrolled into the study.The patients received docetaxel 45 mg/m2 on day 1,8;5-FU 375 mg/m2 infused with an ambulatory pump on day 1 to 5;and cisplatin 20mg/m2 on day 1 to 5,repeated every 28 days at least 2 courses.All patients were assessable for toxicity and response to treatment.Results:Three complete responses and fourteen partial responses were observed.Stable disease was observed in fifteen patients,with progressive disease in the other four patients overall response rate was 44.1%.Median time to progression (TTP) and median overall survival (OS) were 6.1 and 9.3 months,respectively.The one year survival rate was 28.2%.No significant difference existed between the initial and retreated patients (RR,52.6% vs 33.3%,P>0.05).The most common toxicities were myelosuppression,nausea/vomiting and alopecia.The severity of these side effects were grade Ⅰ-Ⅱ,and well tolerated.Myelosuppression was dose limiting toxicity,grade Ⅲ-Ⅳ hypolekocytosis was 23.5%(8/34) and 79.4%(27/34) in total.Conclusion:Docetaxel combined with cisplatin and 5-fluorouracil is a safe and effective regimen in the treatment of advanced gastric cancer.The toxicity and side effects are tolerable.更多还原